Searched for
KOUR NANGRA
HCL, Infosys, TechM good stocks to buy for long-term investors: Nangra"We're recommending largecap companies like HCL, Infosys, at these valuations."- Cipla surges over 6% despite weak Q2 numbersThe company said total revenues for the quarter increased 8.6 per cent on a YoY basis to Rs 3,671.88 crore from Rs 3,379.35 crore reported ...
- We have buy call on Sun Pharma, Ranbaxy: Sarabjit Kour Nangra, Angel BrokingLupin is correcting to realistic levels
- Despite warning letter, Ipca Lab still a top return generator: Sarabjit Kour Nangra, Angel BrokingIn a chat with ET Now, Sarabjit Kour Nangra, Angel Broking, says since Ipca was already under import alert, the warning letter now means th...
- Neutral rating on Cipla, Sun Pharma no game changer: Sarabjit Kour Nangra, Angel Broking, Pharma"ANDA approval will add to the company but since the company is so big that such small approvals do not add significantly."
- Infosys' topline a positive surprise; revenue growth commendable: Sarabjit Kour Nangra, Angel Broking"They have not given any idea on their guidance for the full year so far, but I guess the way they have been doing, they should be able to ...
- Tech Mahindra and many small caps have indicated trend of lower revenue for Q1: Sarabjit Kour Nangra, Angel Broking"Most of the IT companies have been pointing towards a healthy (revenue filled) full year, which should entail a healthy first quarter."
- Most of large-cap pharma stocks are pretty balanced in terms of valuation: Sarabjit Kour Nangra, Angel BrokingI believe the overall stock reaction today is in view of the same. Secondly, Sun Pharma management has refrained from giving any guidance f...
- Lupin shares fall over 3% on disappointing Q4 earningsThe stock ended 3.35 per cent lower at Rs 1,690.60 on the BSE. During the day, it slipped 3.95 per cent to Rs 1,680.
- Infosys guidance a sure sign that they mean business: Sarabjit Kour Nangra, Angel BrokingThey have been guiding again and again that FY17 onwards, they expect Infosys to be back being the bellwether company in terms of the IT se...
- Infosys PAT higher than our expectations: Sarabjit Kour Nangra, Angel Broking"Sales are in line, as you said, and definitely even PAT is higher than our expectations."
- Tech Mahindra acquires US-based LCC; stock hits 52-week highThis is the largest acquisition for Tech Mahindra and is expected to close by 4QFY2015. It will be financed through cash.
- IPCA Laboratories stock slumps 16 per centShares of IPCA Laboratories slumped nearly 16 per cent to hit its 52-week low in early trade amid reports of stock downgrade.
- Sun Pharma shares fall over 2%; slip for second day in a row on US FDA concernsThe stock has fallen on reports that Halol plant in Gujarat has been subjected to surprise inspection by the American drug regulator USFDA.
- Sun Pharma falls 6% as USFDA inspects Halol unit; facility contributes 40% of US salesThe facility is important for the company as its contributes to around 40 per cent of US sales and around 25 per cent of consolidated profi...
- Sanofi India shares tank over 10% on price control orderSanofi India's stock tanked 10.22 per cent to settle at Rs 2,900. In intra-day trade, the scrip plunged 10.99 per cent to Rs 2,875.
- Lupin gains post Q4 results;brokerages raise target priceLupin reported a net profit of Rs 553 cr for the quarter ended March 204, up 35.5%, from Rs 408 cr in the corresponding quarter last fiscal.
- Ranbaxy shares settle 1.51 per cent down; market capitalisation erodes by Rs 43 croreShares of Ranbaxy Laboratories today settled for the day with losses of 1.51 %, pursuant to which the market capitalisation eroded by Rs 43...
- Expect robust numbers for Ranbaxy: Sarabjit Kour Nangra, Angel BrokingIn an interview with ET Now, Sarabjit Kour Nangra, VP–Research-Pharma, Angel Broking, shares her views on some pharma stocks. Excerpts:
- Expect 18% top line growth for Lupin in Q2: Sarabjit Kour Nangra, Angel BrokingIn an interview with ET Now, Sarabjit Kour Nangra, VP–Research: Pharma, Angel Broking, gives her views on Lupin’s expected earnings. Excerp...
Load More
